Axsome Malta vs. Aurobindo Pharma: Solriamfetol Patent Case Consolidated in New Jersey

Introduction

When a pharmaceutical patent dispute spans multiple civil actions filed in rapid succession, the procedural mechanics of consolidation become as strategically significant as the underlying infringement claims themselves. In Axsome Malta, Ltd. v. Aurobindo Pharma, Ltd. (Case No. 2:24-cv-10619, D.N.J.), a solriamfetol oral tablet patent infringement action filed in November 2024 was administratively terminated and folded into a consolidated proceeding alongside related cases—a resolution that signals both the complexity of pharmaceutical patent litigation and the efficiency-driven approaches courts increasingly favor in multi-action ANDA-adjacent disputes.

Filed on November 20, 2024, and closed on June 10, 2025, after 202 days, this case centered on U.S. Patent No. US12090126B2 and Aurobindo Pharma’s alleged infringement through its generic equivalent of Sunosi® (solriamfetol) oral tablets. For patent litigators, IP professionals, and R&D teams operating in the pharmaceutical space, the case’s procedural trajectory offers critical insight into how courts manage parallel pharmaceutical patent infringement actions.

Case Overview

The Parties

The Patent at Issue

The asserted patent, U.S. Patent No. US12090126B2 (Application No. US18/491311), covers formulation and/or method claims relating to solriamfetol oral tablets. The patent protects the commercial embodiment found in Sunosi® at equivalent doses of 75 mg base and 150 mg base—the two commercially available strengths.

• • US12090126B2 — Formulation and/or method claims relating to solriamfetol oral tablets.

Litigation Timeline & Procedural History

Milestones

The case was filed in the U.S. District Court for the District of New Jersey—the preeminent forum for pharmaceutical patent litigation in the United States, owing to the concentration of major pharmaceutical companies headquartered in the state and the court’s deep bench experience with Hatch-Waxman litigation.

Outcome & Verdict Cause Analysis

Civil Action No. 2:24-cv-10619 did not proceed to trial or substantive dispositive motion practice in isolation. Instead, it was consolidated with related Civil Action Nos. 25-643 and 25-3721 into a single Consolidated Action proceeding on the schedule previously established in the lead case, Civil Action No. 24-10617 (D.I. 16). The administrative termination of this docket number, alongside the two companion cases, reflects a standard judicial efficiency mechanism applied when overlapping patents, parties, or products generate parallel filings.

The case was administratively terminated pursuant to a consolidation order. The court ordered that: “All filings going forward shall be filed in the Consolidated Action and that Civil Action Nos. 24-10619, 25-643 and 25-3721 shall be administratively terminated by the Clerk’s office.”

The Consolidated Action proceeds on the scheduling order previously entered in Civil Action No. 24-10617 (D.I. 16). No damages award was issued, and no injunctive relief was entered at this stage—the substantive merits of the patent infringement claims remain pending within the consolidated proceeding. The 202-day timeline from filing to administrative closure is consistent with early-stage consolidation rulings, occurring well before any Markman hearing or summary judgment briefing.

Industry & Competitive Implications

The Axsome Malta v. Aurobindo Pharma dispute reflects a broader pharmaceutical industry dynamic: brand-name CNS drug manufacturers are aggressively defending market exclusivity through patent portfolio assertion as generic challengers accelerate ANDA filings. Sunosi® occupies a growing but competitive segment of the sleep disorder treatment market, and any successful generic entry at the 75 mg and 150 mg equivalent base strengths would substantially erode Axsome’s pricing power and market share.

For the generic pharmaceutical sector, Aurobindo’s challenge represents an industry-standard lifecycle management pressure test. Generic manufacturers routinely file ANDAs for commercially significant CNS drugs as patent cliffs approach, and the District of New Jersey’s consolidated docket management approach means that the resolution of the lead case (24-10617) will effectively govern the outcome for all related actions, including this one.

From a licensing and settlement perspective, the consolidation of four related civil actions increases the incentive for negotiated resolution. Multi-case consolidations often create structured settlement leverage—particularly where a brand holder seeks to avoid adverse claim construction rulings that could weaken broader portfolio positions.

Companies operating in the solriamfetol, DNRI, or adjacent CNS treatment space should monitor the Consolidated Action’s progression through claim construction and any dispositive motion practice for guidance on the scope of US12090126B2’s enforceable claims.